ADC Therapeutics announced updated data from a Phase 2 multicenter investigator-initiated trial (IIT) of ZYNLONTA as a monotherapy for relapsed/refractory marginal zone lymphoma (r/r MZL), presented at the 18th International Conference on Malignant Lymphoma (ICML). The data, with a February 10, 2025 cutoff, included 26 efficacy-evaluable patients out of 27 enrolled.
The study demonstrated an overall response rate (ORR) of 85% and a complete response (CR) rate of 69%. Importantly, 17 of 18 patients who achieved a CR maintained it, with the longest duration of CR reaching 27 months from the start of treatment.
ZYNLONTA was generally well tolerated, with a safety profile consistent with its known characteristics. The trial is expanding enrollment to 50 patients with r/r MZL, adding Emory Winship Cancer Institute and Vanderbilt-Ingram Cancer Center, and the company plans to pursue a regulatory pathway and Compendia inclusion based on these results.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.